newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Praxis Precision Medicines granted restricted stock unit awards covering 6,876 shares of common stock to six new non-executive employees.
  • The awards were issued on November 3, 2025, under the company's 2024 Inducement Plan as inducements for new employment.
  • The grants comply with Nasdaq Listing Rule 5635(c)(4) regarding equity awards for individuals not previously employed by the company.
  • The restricted stock units will vest in four equal annual installments contingent on continued employment.
  • Praxis is a clinical-stage biopharmaceutical company developing therapies for CNS disorders using its Cerebrum™ small molecule platform & Solidus™ antisense oligonucleotide platform.
  • The company maintains a diversified portfolio with four clinical-stage product candidates targeting epilepsy & movement disorders.